Logo image of INO

INOVIO PHARMACEUTICALS INC (INO) Stock Price, Quote, News and Overview

NASDAQ:INO - Nasdaq - US45773H4092 - Common Stock - Currency: USD

1.85  0 (0%)

INO Quote, Performance and Key Statistics

INOVIO PHARMACEUTICALS INC

NASDAQ:INO (4/23/2025, 12:21:23 PM)

1.85

0 (0%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High13.44
52 Week Low1.42
Market Cap67.84M
Shares36.67M
Float35.94M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)05-12 2025-05-12
IPO12-08 1998-12-08


INO short term performance overview.The bars show the price performance of INO in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 -20 -40 -60

INO long term performance overview.The bars show the price performance of INO in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of INO is 1.85 USD. In the past month the price decreased by -1.6%. In the past year, price decreased by -82.5%.

INOVIO PHARMACEUTICALS INC / INO Daily stock chart

INO Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 17.3 309.62B
AMGN AMGEN INC 13.99 149.08B
GILD GILEAD SCIENCES INC 22.83 131.19B
VRTX VERTEX PHARMACEUTICALS INC 1690.24 126.01B
REGN REGENERON PHARMACEUTICALS 12.83 64.01B
ARGX ARGENX SE - ADR 321.87 36.55B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 31.26B
BNTX BIONTECH SE-ADR N/A 27.44B
ONC BEIGENE LTD-ADR N/A 26.83B
SMMT SUMMIT THERAPEUTICS INC N/A 22.86B
NTRA NATERA INC N/A 20.06B
BIIB BIOGEN INC 7.13 17.18B

About INO

Company Profile

INO logo image Inovio Pharmaceuticals, Inc. engages in the provision of designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus. The company is headquartered in Plymouth Meeting, Pennsylvania and currently employs 122 full-time employees. The firm is focused on developing and commercializing deoxyribonucleic acid (DNA) medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines pipeline include INO-3107 for HPV-related recurrent respiratory papillomatosis (RRP); INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma, or OPSCC; VGX-3100 for the treatment of Anal or Perianal HSIL; INO-5401 for the treatment of Glioblastoma Multiforme (GBM), and INO-5401 for the Treatment of Glioblastoma Multiforme (GBM). Its lead candidate is INO-3107 for the treatment of RRP, a rare and debilitating disease of the respiratory tract caused by HPV infection. Its DNA medicines platform consists of DNA plasmids and its CELLECTRA devices, which are used to deliver the DNA plasmids into the cell. Its CELLECTRA device portfolio consists of two models.

Company Info

INOVIO PHARMACEUTICALS INC

660 W. Germantown Pike, Suite 110

Plymouth Meeting PENNSYLVANIA 19462 US

CEO: J. Joseph Kim

Employees: 127

Company Website: https://www.inovio.com/

Investor Relations: https://ir.inovio.com

Phone: 18584103134

INOVIO PHARMACEUTICALS INC / INO FAQ

What is the stock price of INOVIO PHARMACEUTICALS INC today?

The current stock price of INO is 1.85 USD.


What is the ticker symbol for INOVIO PHARMACEUTICALS INC stock?

The exchange symbol of INOVIO PHARMACEUTICALS INC is INO and it is listed on the Nasdaq exchange.


On which exchange is INO stock listed?

INO stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for INOVIO PHARMACEUTICALS INC stock?

10 analysts have analysed INO and the average price target is 7.99 USD. This implies a price increase of 331.89% is expected in the next year compared to the current price of 1.85. Check the INOVIO PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is INOVIO PHARMACEUTICALS INC worth?

INOVIO PHARMACEUTICALS INC (INO) has a market capitalization of 67.84M USD. This makes INO a Micro Cap stock.


How many employees does INOVIO PHARMACEUTICALS INC have?

INOVIO PHARMACEUTICALS INC (INO) currently has 127 employees.


What are the support and resistance levels for INOVIO PHARMACEUTICALS INC (INO) stock?

INOVIO PHARMACEUTICALS INC (INO) has a support level at 1.71 and a resistance level at 1.86. Check the full technical report for a detailed analysis of INO support and resistance levels.


Is INOVIO PHARMACEUTICALS INC (INO) expected to grow?

The Revenue of INOVIO PHARMACEUTICALS INC (INO) is expected to grow by 2320.42% in the next year. Check the estimates tab for more information on the INO EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy INOVIO PHARMACEUTICALS INC (INO) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does INOVIO PHARMACEUTICALS INC (INO) stock pay dividends?

INO does not pay a dividend.


When does INOVIO PHARMACEUTICALS INC (INO) report earnings?

INOVIO PHARMACEUTICALS INC (INO) will report earnings on 2025-05-12.


What is the Price/Earnings (PE) ratio of INOVIO PHARMACEUTICALS INC (INO)?

INOVIO PHARMACEUTICALS INC (INO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.99).


What is the Short Interest ratio of INOVIO PHARMACEUTICALS INC (INO) stock?

The outstanding short interest for INOVIO PHARMACEUTICALS INC (INO) is 15.64% of its float. Check the ownership tab for more information on the INO short interest.


INO Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

INO Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to INO. While INO seems to be doing ok healthwise, there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

INO Financial Highlights

Over the last trailing twelve months INO reported a non-GAAP Earnings per Share(EPS) of -3.99. The EPS increased by 35.23% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -94.75%
ROE -156.57%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%46.43%
Sales Q2Q%13.98%
EPS 1Y (TTM)35.23%
Revenue 1Y (TTM)-73.82%

INO Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 78% to INO. The Buy consensus is the average rating of analysts ratings from 10 analysts.

For the next year, analysts expect an EPS growth of 40.31% and a revenue growth 2320.42% for INO


Ownership
Inst Owners35.91%
Ins Owners0.58%
Short Float %15.64%
Short Ratio6.5
Analysts
Analysts78
Price Target7.99 (331.89%)
EPS Next Y40.31%
Revenue Next Year2320.42%